A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis

BACKGROUND: The standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC study. Although multiple Japanese phase II studies have shown high efficacy and tolerability of CRT with cisplatin plus S-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hisashi, Tanzawa, Shigeru, Misumi, Toshihiro, Makiguchi, Tomonori, Inaba, Megumi, Honda, Takeshi, Nakamura, Junya, Inoue, Koji, Kishikawa, Takayuki, Nakashima, Masanao, Fujiwara, Keiichi, Kohyama, Tadashi, Ishida, Hiroo, Kuyama, Shoichi, Miyazawa, Naoki, Nakamura, Tomomi, Miyawaki, Hiroshi, Oda, Naohiro, Ishikawa, Nobuhisa, Morinaga, Ryotaro, Kusaka, Kei, Fujimoto, Nobukazu, Fukuda, Yasushi, Yasugi, Masayuki, Tsuda, Takeshi, Ushijima, Sunao, Shibata, Kazuhiko, Shibayama, Takuo, Bessho, Akihiro, Kaira, Kyoichi, Shiraishi, Kenshiro, Matsutani, Noriyuki, Seki, Nobuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772940/
https://www.ncbi.nlm.nih.gov/pubmed/36570411
http://dx.doi.org/10.1177/17588359221142786

Ejemplares similares

Ejemplares similares